Navigation Links
HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
Date:3/12/2009

The HemAway Seat(R) offers relief for sufferers of prolapsed internal hemorrhoids

BERKELEY HEIGHTS, N.J., March 12 /PRNewswire/ -- HemAway(R) (www.HemAway.com) announced today the launch of its first FDA-cleared consumer product, the HemAway Seat(R), a painless, non-invasive, discreet, and easy-to-use hemorrhoid treatment device that alleviate the discomfort and agony of prolapsed internal hemorrhoids within minutes of use.

Fitted for seamless and discreet installation on most toilet models, the HemAway Seat naturally uses one's body weight to allow the prolapsed internal hemorrhoid to gently withdraw back into the body, relieving pain, discomfort, and irritation.

HemAway is the brainchild of founder and developer Dr. John Maurello, a practicing chiropractor and long-time sufferer of internal hemorrhoids that would not respond to available treatments and surgery. He created the HemAway Seat upon making a life-changing discovery that eliminated the discomfort of his debilitating condition and allowed him to reclaim his quality of life. "Once I realized its efficacy, I knew the seat would prove to be a welcomed relief for the millions of hemorrhoid sufferers seeking a simple, painless, effective solution to help heal and manage their condition," states Dr. Maurello.

The HemAway Seat fills an urgent need for millions of sufferers who seek alternatives to the few available treatments for internal hemorrhoids. Hemorrhoid creams and home remedies are marginally helpful and at best reduce swelling or mask the pain of the condition. Invasive procedures are the only other available therapies and force patients to face the risks of hemorrhoid surgeries such as permanent incontinence. Dr. Maurello adds, "There is a void for effective treatments that are non-invasive and risk-free."

Approximately half of all Americans experience hemorrhoids by the age of 50 [source: NIH] and 70 percent of women suffer from hemorrhoids at some point during pregnancy or after delivery. [source: Francis-Cheung, Theresa. Pregnancy Weight Management. Adams Media, 2000, p.124.] According to one clinical study, 41 percent of advanced-stage hemorrhoid sufferers were unsatisfied with the results of surgical removal. [source: Surg Endosc. 2008 Nov; 22(11):2379-83. Epub 2008 Jul 12.] These hemorrhoid statistics clearly indicate the need for a product like the HemAway Seat that effectively treats chronic hemorrhoids so that drastic and painful invasive procedures can be avoided and helps sufferers manage the condition when surgical treatments fail.

The HemAway Seat is available for purchase at HemAway.com in both home ($199) and travel models ($129).

About HemAway

Founded by serial entrepreneurs and seasoned medical professionals in 2007, HemAway(R) is a medical device company based in Berkeley Heights, NJ with a mission to develop and market innovative products to meet common medical problems. In early 2009, HemAway launched its first consumer product, the HemAway Seat(R). Cleared for marketing by the FDA, the HemAway Seat was developed specifically to bring relief to the sufferers of prolapsed internal hemorrhoids. HemAway supports American businesses by insuring all products are designed and manufactured in the US. For more information, visit www.HemAway.com.

    CONTACT: Esther Koo, Southard Communications
    212.777.2220/esther@southardinc.com


'/>"/>
SOURCE HemAway
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: